Ovarian Cancer Clinical Trial
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced ovarian epithelial cancer.
Full Description
OBJECTIVES:
Determine the toxicity and tolerance of sequential therapy with prolonged
Determine the response rate and time to progression in this patient
Determine the relative pharmacokinetics of IV and prolonged oral administration of topotecan in the same patients and compare the pharmacodynamics of topo-1 inhibition when given by IV or oral route.
OUTLINE:
Regimen A: Patients receive cisplatin IV over 60-90 minutes on day 1 of each course. Topotecan IV is administered continuously on days 1-14 of course 1. Oral topotecan is administered twice daily on days 1-14 for courses 2, 3, and 4. Treatment repeats every 28 days for 4 courses.
Regimen B: After completion of regimen A, patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
PROJECTED ACCRUAL: A total of 30 patients (15 per arm) will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed advanced ovarian epithelial carcinoma, regardless of quantity of disease post-surgery
Stage IC, II, III, or IV
PATIENT CHARACTERISTICS:
Age:
18 and over
Performance status:
ECOG 0-2
Life expectancy:
Not specified
Hematopoietic:
Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 100,000/mm^3
Hepatic:
SGOT no greater than 3 times upper limit of normal
Bilirubin no greater than 2.0 mg/dL
No clinically significant hepatic disorder
Renal:
Creatinine no greater than 1.5 mg/dL OR
Creatinine clearance greater than 60 mL/min
No clinically significant renal disorder
Cardiovascular:
No clinically significant cardiovascular condition
Other:
Normal GI function allowing reliable administration of oral medication
No active infection requiring systemic medical therapy within past week
No other clinically significant medical condition (e.g., endocrine/metabolic or autoimmune disorder)
No other prior malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
No dementia or altered mental status that would preclude consent
Not pregnant
Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
No prior chemotherapy for ovarian epithelial carcinoma
Endocrine therapy:
Not specified
Radiotherapy:
No prior radiotherapy for ovarian epithelial carcinoma
Surgery:
See Disease Characteristics
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
Bronx New York, 10461, United States
Fresh Meadows New York, 11365, United States
New York New York, 10011, United States
New York New York, 10016, United States
New York New York, 10019, United States
New York New York, 10021, United States
New York New York, 10029, United States
New York New York, 10032, United States
Valhalla New York, 10595, United States
Madison Wisconsin, 53792, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.